Determining the Diagnostic Strength of Serum Tumor Markers in Epithelial Ovarian Cancer in Women from Lahore, Pakistan
DOI:
https://doi.org/10.21649/akemu.v30i3.5461Keywords:
CA125, , CA15-3, , Correlation, FIGO, HE4,, Ovarian CancerAbstract
Background: Ovarian cancer is tagged as deadly condition worldwide. The delay in diagnosis due to late presentation and lack of specific screening tests. HE4 and CA15-3 are considered as noninvasive marker with varied cut off reference and sensitivity, specificity among various populations.
Objective: The objective of this study was to investigate correlation along with sensitivity, specificity, PPV, NPV of HE4, CA15-3 and CA125 among epithelial ovarian cancer.
Methods: This cross section comparative study was conducted on 70 diagnosed ovarian cancer cases age (20 to ≥70) year of any FIGO stage (I-IV after approval from IRB and ethical review board (UHS/Reg-17/ERC-4659) of University of Health sciences. The blood samples were taken and serum levels of HE4 and CA15-3 were measured by ELISA. While CA125 was determined from patient investigation reports.
Results: This study found positive correlation (r=0.089 p=0.66) between malignant and borderline ovarian tumors for HE4, while negative correlation between early (I and II) and advanced (stage III and IV) FIGO stage with r=-0.028 p=0.876. Whereas, for CA15-3 negative correlation was observed with r= -0.006 p=0.980 between malignant and borderline variants of epithelial ovarian cancer and also negative correlation was seen between early (I and II) and advanced (stage III and IV) FIGO stage with r= -0.095 p=0.588.
Conclusions: The discriminative strength of HE4 as biomarker determined by ROC curve was 0.55%. Hence HE4 can be used for diagnosis or prognosis of ovarian cancer.
References
Hariyano, Winarto, Bismarck JL, Laila N. Modification of cut off values for HE4,CA125,the risk of malignancy index and the risk of malignancy algorithm for ovarian cancer detection in Jakarta, Indonesia. Asian Pac J Cancer Prev. 2014; 15(5):1949-1953.
Kehoe S. FIGO staging in ovarian carcinoma and histological subtypes. J Gynecol Oncol. 2020; 31(4): e70.
Liu J, Wang HL, Ma FM, Guo HP, Fang NN, Wang SS, et al. Systematic module approach identifies altered genes and pathways in four types of ovarian cancer. Mol Med Rep. 2017; 16(6): 7907-7914.
Tang Q, Atiq W, Mahnoor S, Abdel-Maksoud MA, Aufy M, Yaz H, et al. Comprehensively analyzing the genetic alterations, and identifying key genes in ovarian cancer. Oncol Res. 2023; 31(2): 141-156.
Charkhchi P, Cybulski C, Gronwald J, Wong FO, Narod SA, Akbari MR. CA125 and Ovarian Cancer: A Comprehensive Review. Cancers. 2020; 12(12): 3730.
Yuan Q, Song J, Yang W, Wang H, Huo Q, Yang J, et al. The effect of CA125 on metastasis of ovarian cancer: old marker new function. Oncotarget. 2017; 8(30): 50015-50022.
Chen Z, Liang Q, Zeng H, Zhao Q, Guo Z, Zhong R, et al. Exosomal CA125 as A Promising Biomarker for Ovarian Cancer Diagnosis. J Cancer. 2020; 11(21): 6445-6453.
Kang KN, Koh EY, Jang JY, Kim CW. Multiple biomarkers are more accurate than a combination of carbohydrate antigen 125 and human epididymis protein 4 for ovarian cancer screening. Obstet Gynecol Sci. 2022; 65(4): 346-354.
Yılmaz EP, Kumtepe Y. Endometrial and Ovarian Cancer with MR Imaging Importance of Serum HE4 and CA 125 Levels in the Extent of Disease at Evaluation. Eurasian J Med. 2016; 48(3): 192-198.
Abu Hassaan SO. Monitoring ovarian cancer patients during chemotherapy and follow-up with the serum tumor marker CA125. Dan Med J. 2018; 65(4): B5463.
Kang KN, Koh EY, Jang JY, Kim CW. Multiple biomarkers are more accurate than a combination of carbohydrate antigen 125 and human epididymis protein 4 for ovarian cancer screening. Obstet Gynecol Sci, 2022; 65(4): 346–354.
Anastasi E, Farina A, Granato T, Colaiacovo F, Pucci B, Tartaglione S, et al. Recent Insight about HE4 Role in Ovarian Cancer Oncogenesis. Int J Mol Sci. 2023; 24(13): 10479.
Braicu EI, Krause CL, Torsten U, Mecke H, Richter R, Hellmeyer L, et al. HE4 as a serum biomarker for the diagnosis of pelvic masses: a prospective, multicenter study in 965 patients. BMC Cancer. 2022; 22(1): 831.
Suri A, Perumal V, Ammalli P, Suryan V, Bansal SK. Diagnostic measures comparison for ovarian malignancy risk in Epithelial ovarian cancer patients: a meta-analysis. Sci Rep. 2021; 11(1): 17308.
Yang S, Tang J, Rong Y, Wang M, Long J, Chen C, et al. Performance of the IOTA ADNEX model combined with HE4 for identifying early-stage ovarian cancer. Front Oncol. 2022; 12: 949766.
AlSomairi A, Himayda S, Altelmesani A, Lee YJ, Lee JY. Prognostic value of HE4 in advanced-stage, high-grade serous ovarian cancer: Analysis of HE4 kinetics during NACT, predicting surgical outcome and recurrence in comparison to CA125. Gynecol Oncol, 2024; 181: 155-161.
Barr CE, Funston G, Jeevan D, Sundar S, Mounce LTA, Crosbie EJ. The Performance of HE4 Alone and in Combination with CA125 for the Detection of Ovarian Cancer in an Enriched Primary Care Population. Cancers. 2022; 14(9): 2124.
Barani M, Bilal M, Sabir F, Rahdar A, Kyzas GZ. Nanotechnology in ovarian cancer: Diagnosis and treatment. Life Sci. 2021; 266(1): 18914.
Matsas A, Stefanoudakis D, Troupis T, Kontzoglou K, Eleftheriades M, Christopoulos P, et al. Tumor Markers and Their Diagnostic Significance in Ovarian Cancer. Life (Basel). 2023;13(8): 1689.
Li M, Men X, Zhang X. Diagnostic value of carbohydrate antigen 72-4 combined with carbohydrate antigen 15.3 in ovarian cancer, cervical cancer and endometrial cancer. J BUON. 2020; 25(4): 1918-1927.
Seale KN, Tkaczuk KHR. Circulating Biomarkers in Breast Cancer. Clin Breast Cancer. 2022; 22(3): e319-e331.
Bel'skaya LV, Sarf EA, Loginova AI, Vyushkov DM, Choi ED. Potential Diagnostic Value of Salivary Tumor Markers in Breast, Lung and Ovarian Cancer: A Preliminary Study. Curr Issues Mol Biol. 2023; 45(6): 5084-5098.
Chudecka-Głaz A, Strojna A, Michalczyk K, Wieder-Huszla S, Safranow K, Skwirczyńska E, et al. Evaluation of He4 Use in the Diagnosis of Ovarian Cancer: First and Second Recurrence, and an Analysis of HE4 Concentration during Second- and Third-Line Chemotherapy. Diagnostics (Basel). 2023; 13(3): 452.
Sagi-Dain L, Lavie O, Auslander R, Sagi S. Clinical Use and Optimal Cutoff Value of Ca15-3 in Evaluation of Adnexal Mass: Retrospective Cohort Study and Review of the Literature. Am J Clin Oncol. 2018; 41(9): 838-844.
WMA, World Medical Association (2020) WMA declaration of Helsinki-ethical principles for medical research involving human subjects. Adopted by the 18th WMA General Assembly, Helsinki, Finland, June 1964 and amended by the:64th WMA General Assembly, Fortaleza, Brazil, October 2013. Available from: https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects.
Nam JE, Yoon H, Kim SW, Kim H, Kim YT, Kim JH, et al. MicroRNA Expression Profiles in Serous Ovarian Carcinoma. Clin Cancer Res. 2008; 14(9): 2690-2695.
Terzic M, Dotlic J, Likic I, Nikolic B, Brndusic N, Pilic I, et al. Diagnostic value of serum tumor markers for adnexal masses. Eur J Med. 2014; 9(3): 417-423.
Akhtar N, Rajan S, Kumar V, Sharma S, Qayoom S, Mukjarjee S, et al. Serum HE4 Detects Ovarian Cancer Recurrence Earlier Than CA 125: Indian Study. J Clin Diag Res. 2018; 12(5): XC01-XC03.
Xi QP, Pu DH, Lu WN. Research on application value of combined detection of serum CA125, HE4 and TK1 in the diagnosis of ovarian cancer. Eur Rev Med Pharmacol Sci. 2017; 21(20): 4536-41.
Gemer O, Oustinov N, Gdalevich M, Dubnik S, Levy R, Yachnin A, et al. Pretreatment CA 15-3 levels do not predict disease-free survival in patients with advanced epithelial ovarian cancer. Tumori. 2013; 99(2): 257-60.
Dolscheid-Pommerich RC, Keyver-Paik M, Hecking T, Kuhn W, Hartmann G, Stoffel-Wagner B, et al. Clinical performance of LOCI™-based tumor marker assays for tumor markers CA 15-3, CA 125, CEA, CA 19-9 and AFP in gynecological cancers. Tumour Biol. 2017; 39(10): 1010428317730246.
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Annals of King Edward Medical University
This work is licensed under a Creative Commons Attribution 4.0 International License.
This is an open-access journal and all the published articles / items are distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. For comments publications@kemu.edu.pk